Aims: Multiple myeloma (MM) is an incurable hematological cancer with a higher rate of relapse. Alterations in the function of long non-coding RNAs (lncRNAs) promote the progression and metastasis of cancer. We carry out this study to explore the expression profile of differently expressed lncRNAs in newly diagnosed MM. Main methods: The Bone marrows we analyzed were obtained from five MM and five IDA patients (serving as controls). Arraystar Human LncRNA Array V4.0 was used to profile expression of lncRNAs and mRNAs. Gene ontology (GO) and pathway analysis were utilized to understand the biological roles of differently expressed genes, while Database for Annotation, Visualization and Integrated Discovery (DAVID) was used for constructing the lncRNA-mRNA co-expression network. Quantitative polymerase chain reaction (qRT-PCR) was performed to confirm the expressions of dysregulated lncRNAs. Key findings: Bioinformatic analysis of the lncRNA expression identified > 3000 dysregulated lncRNAs (difference ≥ 2-fold) in MM samples. GO and pathway analysis revealed that ECM-receptor and cell cycle pathwayrelated genes were significantly associated with MM. Four dysregulated lncRNAs were confirmed by qRT-PCR. Among them, the expression of ST3GAL6-AS1, LAMA5-AS1and RP11-175D17.3wereassociated with stage and risk status of MM. On the basis of GEO public database analysis, LAMA5-AS1 was related with an overall survival rate of MM patients. Significance: These results reveal the feasible functions of lncRNAs in pathogenesis of MM. Further studies are required to explore whether these lncRNAs could serve as candidate therapeutic targets and new molecular biomarkers for MM.
Introduction
Multiple myeloma (MM), the second most common hematological cancer, is characterized by the accumulation of malignant plasma in the bone marrow and the detectable secretion of monoclonal immunoglobulin in the serum or urine [1, 2] . Significant improvement in outcomes has been observed for myeloma patients in the past few decades, mainly as a result of the use of novel drugs such as proteasome inhibitors [3] and immunomodulatory drugs, together with autologous stem cell transplantation and advancing supportive care [4, 5] . However, further development and identification of prognostic markers or novel targets for MM treatment which could improve the survival rate of MM are still in the mist.
Long non-coding RNA (lncRNA) is emerging as an important regulator of involved in gene regulation at the transcriptional, posttranscriptional and epigenetic levels [6] . Human genomic data have shown that about 62-75% of the human genome is transcribed into RNA, and only 1% codes protein expressions, which indicated that a large number of the genome are compounded as regulators [7, 8] . The dysregulation of lncRNA has been observed to play important roles in the development and progression of a variety of diseases [9] and tumors [10] [11] [12] [13] [14] , such as RGMB-AS1 in lung adenocarcinoma [15] , HOTAIR in breast cancer [16] .
Previous studies showed that the upregulation of lncRNA MALAT1 was proved to play a role in pathogenesis of MM [17, 18] , while the downregulation of KIAA0459 was supposed to take part in the pathogenesis or progression of myeloma [19] . But the comprehensive lncRNA expression profiles of MM are hardly studied.
In the present study, we revealed the differential expression of lncRNAs in MM to gain a better understanding of pathogenesis and https://doi.org/10.1016/j.lfs.2018.01.025 Received 3 October 2017; Received in revised form 18 January 2018; Accepted 22 January 2018 identify possible biomarkers and novel therapeutic targets of MM.
Material and methods

Patients and samples
Approval for this study was obtained from the Ethics Committee of the Second Affiliated Hospital of Xi'an Jiaotong University (Approval number: 2015186). When the written informed consent was obtained from all patients, bone marrow specimens were obtained from newly diagnosed MM patients at the Department of Hematology, Second Affiliated Hospital of Xian Jiaotong University, between 2015 and 2016. The diagnosis, stage and risk status of MM were made in accordance with the National Comprehensive Cancer Network (NCCN) (2015 version 3 &2017 version 3). To weaken the variation on samples as much as possible, bone marrow samples of iron deficiency anemia (IDA) patients were used as controls after informed consent, for the deficiency of bone marrow samples from normal donors in clinic. The general clinical and laboratory features of the five MM patients and five IDA patients are summarized in Table 1. 2.2. Profiling of lncRNA expression by Arraystar Human LncRNA Array V4.0 Arraystar Human LncRNA Microarray V4.0, performed by KangChen Biotech (Shanghai, China), is designed for global profiling of human lncRNAs and protein-coding transcripts, which could detect about 40,173 lncRNAs and 20,730 coding transcripts. Simply, mRNA was purified from total RNA using mRNA isolation kit (mRNA-ONLY™ Eukaryotic mRNA Isolation Kit, Epicentre). Then, each sample was amplified and transcribed into fluorescent cRNA as probes to hybridize to the Human LncRNA Array V4.0. RNA quantity and quality were monitored by NanoDrop ND-1000. Agilent Feature Extraction software (version 11.0.1.1) was used to analyze acquired array images. Differentially expressed lncRNAs and mRNAs were performed with statistical significance (P-value < 0.05) and a cut-off point of 2-fold between two groups.
Gene ontology and Kyoto encyclopedia of genes and genomes pathway analysis
Gene Ontology (GO) Enrichment analysis of differently expressed genes was performed using functional annotation tool Database for Annotation, Visualization and Integrated Discovery (DAVID) (http:// david.abcc.ncifcrf.gov/summary.jsp), and the significant GO terms were identified as a P-value < 0.05. Pathway analysis of differentially expressed genes was performed based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://www.genome.jp/kegg).
Co-expression analysis of lncRNA and mRNA
The screening criteria of dysregulated lncRNA are as follows: i) fold change was > 2.0-fold; ii) P-value was < 0.05; iii) average raw intensities of replicate samples of MM group and the control group was > 100; iv) lncRNAs who located in sex chromosomes were removed.
String (http://www.string-db.org/) is online software to reveal protein-protein interaction network, which was used to track the core mRNAs in the pathogenesis of MM in this study. The dysregulated mRNA whose fold change was > 4.0-fold was included in String analysis.
The lncRNA-mRNA co-expression analysis was performed by Weighted Correlation Network Analysis (WGCNA, https://labs. genetics.ucla.edu/horvath/CoexpressionNetwork/), and the network was then constructed by Cytoscape software (the Cytoscape Consortium, San Diego, CA, USA). K-core scoring was used to identify core transcripts of co-expression networks. The higher k-core score means a more central location of a transcript within a network.
The procedures of searching for the possible co-expression coding gene of lncRNA ST3GAL6-AS1 included the following: i) scan the position of lncRNA in UCSC database (http://genome.ucsc.edu/) to seek for the possible related coding gene according to Flank 10 K theory [23] ; ii) confirm the co-expression relationship between two genes in pan-cancer by CHIPbase v2.0 (http://rna.sysu.edu.cn/chipbase/); iii) validate the expression level of possible target coding gene by qRT-PCR.
RNA isolation and real-time quantitative reverse transcriptionpolymerase chain reactions (qRT-PCR)
Total RNA was extracted from bone marrow mononuclear cells (BMSCs) samples of MM and IDA using TRIzol reagent (Invitrogen, Germany), and stored at −80°C until use. RNA purity and concentration were determined by NanoDrop ND-1000.
RNA samples were reversely transcribed into cDNA using a Primescript RT master mix with Oligo dT primers and random primers in accordance with manufacturer's protocols (Takara). Then, the qRT-PCR was performed by SYBR Premix Ex Taq™ II (TliRNaseH Plus) (Takara) and StepOne Software v2.1, according to manufacturer's instructions. Primers of detected lncRNA and β-actin were designed and synthesized by Invitrogen (Shanghai, China). And the primer sequences were as shown in Table 2 . ΔCt value was used to reflect the expression level of lncRNAs.
GEO datasets of MM
Gene microarray expression data and the related clinical information of the patients with MM used in this study were obtained from publicly available Gene Expression Omnibus (GEO) database, GSE24080 (Affymetrix HG-U133_Plus_2.0 array) (www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GSE24080) [20] .
Statistical analysis
The relative expression level of each lncRNA was representative by △Ct and it was compared between two groups using the Mann-Whitney Wilcoxon rank test. Survival rate was estimated by the life table method and compared using the log-rank test. All tests were two-sided, and P < 0.05 were defined as a significant difference. All statistical analyses were performed with Statistical Product and Service Solutions (SPSS) Statistics for Windows, Version 18.0 (IBM Corp., Armonk, NY, USA).
Results
Differentially expressed lncRNAs and mRNAs in MM
A total of 2445 lncRNAs were upregulated and 1519 lncRNAs were downregulated in four MM bone marrow samples compared with five IDAs. Among them, 199 lncRNAs were significantly upregulated and 27 lncRNAs were notably downregulated more than10-fold in MM sample verses IDAs (Fig. 1A& B) .
Furthermore, a total of 3782 differentially expressed mRNAs were identified in MM, in which, 1404 were upregulated and 2378 were downregulated (Fig. 1C) . Table 2 The primer sequences of the detected lncRNA.
Name
Forward primer (5′-3′) Reverse primer (5′-3′) The top ten enriched pathways in downregulated transcripts.
Identification of differentially expressed lncRNA in MM
The dysregulated lncRNAs are widely distributed among all chromosomes covering sex chromosomes X and Y, but the chromosome Y is not exhibited in the following figure for the reason that IDA control group we used were all female in microarray analysis ( Fig. 2A) . According to the association with annotated protein-coding genes, lncRNA was divided into six subgroups, including natural antisense (4.7%), intronic antisense (4.4%), intron sense-overlapping (1.7%), exon senseoverlapping (0.7%), intergenic (19.2%) and bidirectional (1.6%). The counts and types of the dysregulated lncRNAs in this study was shown in Fig. 2B , and there are still many lncRNAs (67.7%) not be well-annotated. A certain number of the cross was found in four categories, that is natural antisense, intronic antisense, intron sense-overlapping and exon sense-overlapping (Fig. 2C) , which indicate the complex relationship between lncRNAs and protein-coding genes.
Dysregulated lncRNA-related gene pathways in MM
Some lncRNAs could regulate the gene expression of neighboring and overlapping coding gene [21, 22] . Hence, the function of differential expressed lncRNAs might be reflected by related mRNAs expression. On this basis, the molecular mechanism and related pathways of differently expressed mRNAs were generated by DAVID tool to gain insight into the functions of lncRNAs. The top ten enriched biological process (BP) by upregulated transcripts were involved in multicellular organismal development and cell-cell adhesion, while downregulated transcripts were dragged in mitotic cell cycle and cell cycle (Fig. 3A &  B) . KEGG pathway analysis of the top ten enriched pathways included extracellular matrix (ECM) -receptor interaction and phosphatidylinositol 3-kinase (PI3K)/AKT pathway in upregulated transcript, while cell cycle and DNA replication were the top two enriched pathways in downregulated transcript (Fig. 3C & D) .
Furthermore, we use String tool to find core mRNAs in the pathogenesis of MM from all dysregulated mRNAs. As shown in Fig. 4 , the core mRNAs included topoisomerase II A (TOP2A), epidermal growth factor (EGF) and Bone morphogenetic proteins (BMP), which indicated that these mRNAs may play important roles in the development of MM.
LncRNA/mRNA co-expression networks in MM
Co-expression network analysis can be used to identify candidate biomarkers or therapeutic targets of MM. According to our results of microarray, the co-expression network between differentially expressed lncRNAs and mRNAs was analyzed by WGCNA. And the relationship above was visualized by Cytoscape using a Pearson's correlation coefficient no < 0.99 (Fig. 5) . In this complex network, we found two crowded parts, that is, two high K-score groups, which were amplified in Fig. 6 . Combined with P value and change fold, we came up with four candidate lncRNAs in these two high K-score groups for further validation, including ST3 beta-galactoside alpha-2,3-sialyltransferase 6 antisense RNA 1 (ST3GAL6-AS1), laminin subunit alpha 5 antisense RNA 1 (LAMA5-AS1), ZNF663P and RP11-175D17.3.
Furthermore, the co-expression network displayed that one lncRNA may correlate with one to dozens lncRNAs and mRNAs, which suggested that regulation between lncRNAs and mRNAs might be implicated in MM development.
Confirmation and clinical significance of dysregulated lncRNAs in MM
To validate the microarray data, we confirmed the expression of four candidate lncRNAs above in MM bone marrow samples, including 62 newly diagnosed MM, 20 complete remission (CR) MM, 20 refractory/relapse (R/R) MM and 22 IDA (serving as controls) samples using qRT-PCR. Our data revealed that the lncRNA ST3GAL6-AS1, ZNF663P, LAMA5-AS1 and RP11-175D17.3 were significantly upregulated in newly diagnosed MM and R/R MM samples compared with IDA controls and MM patients who got CR (P < 0.05) (Fig. 6 ). There was no significant differences between newly diagnosed MM patients and R/R ones, or MM patients who received CR and IDA controls (P > 0.05) (Fig. 6) . The results are consistent with the microarray assay. Therefore, qRT-PCR results verified the veracity of microarray results.
Furthermore, we analyzed the relationship between expression of these four lncRNAs and characteristics of newly diagnosed MM patients. As shown in Table 3 , the expression level of ST3GAL6-AS1 was associated with D-S (P = 0.021), ISS (P = 0.038), R-ISS stage (P = 0.027), mSMART risk status (P = 0.013) and the percentage of malignant plasma cells in bone marrow (P = 0.031). The LAMA5-AS1 Life Sciences 196 (2018) [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] expression level was shown to be related to D-S (P = 0.038), ISS stage (P = 0.042), mSMART risk status (P = 0.036) and the percentage of malignant plasma cells in bone marrow (P = 0.047). However, the expression of RP11-175D17.3 was only involved in ISS stage (P = 0.039), while ZNF663P was only related to percentage of myeloma cells in bone marrow (P = 0.033). Moreover, in the publicly available GEO database, we assessed the prognostic significance of lncRNA ZNF663P and LAMA5-AS1 in 565 MM patients. The result revealed that high level LAMA5-AS1 predicts a better prognostic of MM (P = 0.024), but not the ZNF663p (P = 0.144) (Fig. 7) .
The possible target coding gene of lncRNA ST3GAL6-AS1
As shown in Fig. 6 , the expression level of ST3GAL6-AS1 was the highest among these four lncRNAs. To preliminarily understand how ST3GAL6-AS1 functions in MM, we had the deeper insight into its possible target. We scan the position of lncRNA in UCSC database and find coding gene ST3 beta-galactoside alpha-2,3-sialyltransferase 6 (ST3GAL6) is located at the upstream of the ST3GAL6-AS1 within 10 K (Fig. 8A) . Based on Flank 10 K theory [23] , we supposed that ST3GAL6-AS1 might regulate ST3GAL6 expression by cis-pattern. The correlation between these two genes was detected by pan-cancer data from CHIP-BASE database, which showed the coefficient was > 0.6 (Fig. 8B) . On account of our microarray data, we verified the up-regulated expression of ST3GAL6 in newly diagnosed MM by qRT-PCR (P > 0.05) (Fig. 8C) , which was consistent with the research before [24] . Furthermore, the co-expression of ST3GAL6-AS1 and ST3GAL6 was analyzed by Pearson correlation coefficient (r = 0.576) (Fig. 8D) .
Discussion
In this study, we gain a landscape of differentially expressed lncRNAs and mRNAs in five newly diagnosed MM by microarray analysis. However, lncRNAs in MM have just begun to be understood, and the majority of them have yet to be studied.
Pathway analysis by KEGG showed that ECM-receptor interaction, PI3K/AKT pathway and cell cycle were highly related to the pathogenesis of MM. It has been reported that the PI3K/AKT signaling pathway plays a critical regulatory role in the pathophysiology of MM, such as survival, proliferation, migration, as well as drug resistance, and has emerged as a crucial therapeutic target [25] . And many novel inhibitors targeting this pathway have been developed and acquired good effect on MM in the basic experiment [26, 27] . Moreover, it was pointed out that a group of ECM proteins, ECM receptors and ECMmodulating enzymes were progressively up-regulated in MM, which was important to the invasion and metastasis of myeloma cells [28, 29] .
Protein interaction analysis showed that these mRNAs, including TOP2A, EGF and BMP, might be the core mRNAs in MM pathogenesis. Some studies showed that the combination of TOP2 and XPO1 inhibitors was highly effective against acquired drug resistance MM samples obtained from patients with relapsed/refractory myeloma [30] . EGF-like growth factor was a growth factor of malignant plasma cells in MM [31] , and an inhibitor of the EGF receptor family blocks myeloma cell growth factor activity [32] . In addition, BMP and receptors were proved to be over-expressed in bone-marrow cells of MM patients and partially protected myeloma cells from bortezomib-and TRAIL-induced apoptosis [33, 34] , and it was the target of lncRNA MEG3 which promotes osteogenic differentiation of mesenchymal stem Fig. 6 . Verification of dysregulated lncRNA expression in multiple myeloma (MM). Expression of MM samples vs. iron deficiency anemia (IDA) samples were analyzed using qRT-PCR, and summarized as mean ± standard error (SE). The relative expression level of each lncRNA was showed by 2 -△Ct value. P < 0.05 was considered statistically significant.
(***P < 0.001, **P < 0.01).
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Life Sciences 196 (2018) [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] cells [35] . These studies are in accordance with our finding that these pathways are deserved to be further studied for potential therapeutic value. Based on bioinformatics analysis, a group of dysregulated lncRNAs was identified by qRT-PCR in this study, including ST3GAL6-AS1, LAMA5-AS1, ZNF663P and RP11-175D17.3. According to clinical characteristics analysis, we found the expression level of ST3GAL6-AS1 and LAMA5-AS1 was associated with disease stage, risk status and the percentage of magnificent plasma cells in bone marrow, but not the gender, age, MM type or chromosome alteration. However, the expression of RP11-175D17.3 was only involved in ISS stage, while ZNF663P was only related to percentage of myeloma cells in bone marrow. This would be the outcome of the small samples. On further investigation, we will devote ourselves to enlarge the number of samples to further clear the relationship between the expression level of the lncRNAs above and the characteristics of MM patients.
A previous study has identified four prognostic lncRNA biomarkers (RP4-803 J11.2, RP1-43E13.2, RP11-553 L6.5, ZFY-AS1) that are significantly associated with overall survival (OS) of patients with MM and developed a lncRNA-focus risk model for survival prediction through integrating lncRNA expression profiles with clinical features of a large cohort of patients with MM [20] . In the present study, we revealed that high expression of LAMA5-AS1 was an index of better prognosis for MM patients using the GEO database, but not the ZNF663P. The other lncRNAs, such as ST3GAL6-AS1, RP11-175D17.3, lose the chance of prognostic analysis because of the absence from the previous GEO database.
The co-expression network of dysregulated lncRNA and mRNA indicated the core lncRNA in the pathogenesis of MM, which might be the footstone of finding importantly potential biomarker and therapeutic target. We picked up four dysregulated lncRNAs from high K-score part of co-expression network, and verified the expression level of them. The results showed the same tendency between microarray and qRT-PCR, which means the way we select candidate lncRNAs was feasible. As for ST3GAL6-AS1, we try to look for its possible target coding gene through present database. As shown in Fig. 8 , the expression relationship between ST3GAL6-AS1 and ST3GL6 was > 0.6 among pan-cancer. Our results revealed that ST3GAL6 expression was higher in MM patients, and Pearson correlation coefficient between ST3GAL6-AS1 and ST3GAL6 was 0.563. ST3GAL6 was up-regulated markedly in MM patients, influencing homing and survival of MM cells [24] . Based on the above, we predicted that ST3GAL6-AS1 may play important role in MM through up-regulating ST3GAL6 expression. Nonetheless, the further relationship and the function of them should be identified by laboratory results. The expression level of ZNF663P had no effect on overall survival of MM patients. 
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Some limitations still exist in our study. First, multiple myeloma is a heterogeneous disease while our sample size of the sequenced bone marrow is so limited. So, our microarray results might not represent an accurate lncRNAs expression profile in newly diagnosed multiple myeloma. Second, we should purify the tumoral plasma cells from the bone marrow of these patients to analyze the expression of lncRNAs related to this disease. In the case of control samples, we should use purified plasma cells from the bone marrow of healthy donors. But the samples of healthy donors are hardly obtained in clinical. Third, the function of differential expressed lncRNAs which were identified in this study has yet to be cleared. Therefore, further in vitro and in vivo experiments are currently needed to be conducted by our group to investigate the biological effects of the aforementioned lncRNAs, and the function of ST3GAL6-AS1 has been studied in our group.
Conclusion
To conclude, the dysregulated lncRNAs and mRNAs expression profile in bone marrow samples of MM are identified and some of them were verified by qRT-PCR. Our data and analysis might be the foundation for further investigation of lncRNAs in MM. These results are helpful to analyze the functions of lncRNAs and provide precious information for exploring candidate therapeutic targets and new molecular biomarkers for newly diagnosed MM.
